Drug evaluation and decision making in Catalonia: development and validation of a methodological framework based on multi-criteria decision analysis (MCDA) for orphan drugs A Gilabert-Perramon, J Torrent-Farnell, A Catalan, A Prat, M Fontanet, ... International Journal of Technology Assessment in Health Care 33 (1), 111-120, 2017 | 59 | 2017 |
Cost analysis of the treatments for patients with advanced Parkinson's disease: SCOPE study F Valldeoriola, J Puig-Junoy, R Puig-Peiró, ... Journal of medical economics 16 (2), 191-201, 2013 | 54 | 2013 |
Impacto económico de las exacerbaciones agudas en EPOC M Pérez, R Puig-Peiró, S Aceituno, L Lizán Rev. patol. respir, 88-95, 2016 | 14 | 2016 |
Understanding variations in relative effectiveness: A health production approach A Towse, B Jonsson, C McGrath, A Mason, R Puig-Peiro, ... International journal of technology assessment in health care 31 (6), 363-370, 2015 | 13 | 2015 |
The use of pay-for-performance for drugs: can it improve incentives for innovation? W García-Fontes, A Towse, L Garrison, R Puig-Peiró Incentives for Research, Development, and Innovation in Pharmaceuticals, 69-80, 2011 | 12 | 2011 |
Projecting expenditure on medicines in the UK NHS P O’Neill, J Mestre-Ferrandiz, R Puig-Peiro, J Sussex PharmacoEconomics 31, 933-957, 2013 | 11 | 2013 |
RS1 literature review on patient access schemes, flexible pricing schemes and risk sharing agreements for medicines R Puig-Peiró, J Mestre-Ferrandiz, J Sussex, A Towse Value in Health 14 (7), A243, 2011 | 9 | 2011 |
Praktische Anwendung der kontinuierlichen Apomorphin-Pumpentherapie L Tönges, A Ceballos-Baumann, H Honig, A Storch, WH Jost Fortschritte der Neurologie· Psychiatrie 85 (09), 516-535, 2017 | 8 | 2017 |
Coste directo de la enfermedad pulmonar obstructiva crónica asociado a variaciones en adherencia y persistencia M Pérez, R Puig-Peiró, S Paz, L Lizán Rev. patol. respir, 49-56, 2015 | 7 | 2015 |
Cost–effectiveness analysis of 5-fluorouracil 0.5%/salicylic acid 10% in the treatment of actinic keratosis in Spain D Nieves, R Puig-Peiro, C Ferrandiz, MJ Plazas, M Brosa Expert Review of Pharmacoeconomics & Outcomes Research 15 (3), 539-543, 2015 | 6 | 2015 |
La financiación del sistema para la autonomía y atención a la dependencia: proyecciones de gasto 2007-2015 D Casado Marín, A Tur Prats, R Puig Peiró Madrid: IMSERSO, 2008 | 6 | 2008 |
Revisión de la evidencia económica sobre el uso de la estimulación cerebralprofunda en la enfermedad de Parkinson avanzada J Puig-Junoy, R Puig Peiró Neurologia 24 (4), 220-9, 2009 | 5 | 2009 |
HT5 Development of a Multi-Criteria Decision Analysis (MCDA) Framework for health care decision-making in catalonia (spain): pilot study focused in orphan drugs A Gilabert-Perramon, J Torrent-Farnell, A Catalan, A Prat, M Fontanet, ... Value in Health 19 (7), A353, 2016 | 3 | 2016 |
Relative effectiveness in breast cancer treatment: A health production approach R Puig-Peiro, A Mason, J Mestre-Ferrandiz, A Towse, C McGrath, ... International Journal of Technology Assessment in Health Care 31 (6), 371-379, 2015 | 3 | 2015 |
International Comparisons of Medicine Prices: 2011 Indices P O’Neill, R Puig-Peiró, J Mestre-Ferrándiz, J Sussex Office of Health Economics, 2012 | 3 | 2012 |
Incentivos a la I+ D+ i de medicamentos WA Garcia-Fontes Springer Science & Business Media, 2012 | 3 | 2012 |
Time trends in NICE HTA decisions ND O’Neill, R Puig-Peiro Office of Health Economics, 2012 | 3 | 2012 |
Researching the relative efficacy and relative effectiveness of medicines across Europe J Mestre-Ferrandiz, R Puig-Peiro, A Towse Contract Research, 2010 | 3 | 2010 |
Developing a modeling framework for quantifying the health and cost implications of antibiotic resistance for surgical procedures H Davies, J Russell, A Varghese, H Holmes, MO Soares, B Woods, ... MDM Policy & Practice 8 (1), 23814683231152885, 2023 | 1 | 2023 |
PSU3 A Framework for Evaluating the Health and Cost Implications of Antimicrobial Resistance in the Context of Surgical Procedures H Davies, J Russell, A Varghese, S Mealing, H Holmes, B Woods, ... Value in Health 23, S738, 2020 | 1 | 2020 |